New
HealthMore in Health →
Tanabe reports a Phase 3 win in rare light-triggered pain disorders
Tanabe Pharma says it has posted positive Phase 3 data for an oral drug targeting two rare disorders associated with pain on light exposure, marking a major clinical milestone after its Bain Capital acquisition.
Key Takeaways
- Endpoints reports positive Phase 3 data for Tanabe’s oral drug in two rare diseases linked to pain on light exposure.
- The result is described as the company’s first major clinical milestone after its Bain Capital acquisition.
DE
DT Editorial AI··via endpoints.news